RCMI Coordinating Center (RCMI CC) Header Logo

Connection

David A. Foster to Phospholipase D

This is a "connection" page, showing publications David A. Foster has written about Phospholipase D.
Connection Strength

8.121
  1. Bernfeld E, Menon D, Vaghela V, Zerin I, Faruque P, Frias MA, Foster DA. Phospholipase D-dependent mTOR complex 1 (mTORC1) activation by glutamine. J Biol Chem. 2018 10 19; 293(42):16390-16401.
    View in: PubMed
    Score: 0.624
  2. Utter M, Chakraborty S, Goren L, Feuser L, Zhu YS, Foster DA. Elevated phospholipase D activity in androgen-insensitive prostate cancer cells promotes both survival and metastatic phenotypes. Cancer Lett. 2018 06 01; 423:28-35.
    View in: PubMed
    Score: 0.603
  3. Mukhopadhyay S, Saqcena M, Chatterjee A, Garcia A, Frias MA, Foster DA. Reciprocal regulation of AMP-activated protein kinase and phospholipase D. J Biol Chem. 2015 Mar 13; 290(11):6986-93.
    View in: PubMed
    Score: 0.486
  4. Foster DA, Salloum D, Menon D, Frias MA. Phospholipase D and the maintenance of phosphatidic acid levels for regulation of mammalian target of rapamycin (mTOR). J Biol Chem. 2014 Aug 15; 289(33):22583-22588.
    View in: PubMed
    Score: 0.467
  5. Xu L, Salloum D, Medlin PS, Saqcena M, Yellen P, Perrella B, Foster DA. Phospholipase D mediates nutrient input to mammalian target of rapamycin complex 1 (mTORC1). J Biol Chem. 2011 Jul 22; 286(29):25477-86.
    View in: PubMed
    Score: 0.377
  6. Toschi A, Lee E, Thompson S, Gadir N, Yellen P, Drain CM, Ohh M, Foster DA. Phospholipase D-mTOR requirement for the Warburg effect in human cancer cells. Cancer Lett. 2010 Dec 18; 299(1):72-9.
    View in: PubMed
    Score: 0.366
  7. Lyo D, Xu L, Foster DA. Phospholipase D stabilizes HDM2 through an mTORC2/SGK1 pathway. Biochem Biophys Res Commun. 2010 May 28; 396(2):562-5.
    View in: PubMed
    Score: 0.350
  8. Foster DA. Reduced mortality and moderate alcohol consumption: the phospholipase D-mTOR connection. Cell Cycle. 2010 Apr 01; 9(7):1291-4.
    View in: PubMed
    Score: 0.348
  9. Shi M, Zheng Y, Garcia A, Xu L, Foster DA. Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras. Cancer Lett. 2007 Dec 18; 258(2):268-75.
    View in: PubMed
    Score: 0.294
  10. Gadir N, Lee E, Garcia A, Toschi A, Foster DA. Suppression of TGF-beta signaling by phospholipase D. Cell Cycle. 2007 Nov 15; 6(22):2840-5.
    View in: PubMed
    Score: 0.290
  11. Rodrik V, Gomes E, Hui L, Rockwell P, Foster DA. Myc stabilization in response to estrogen and phospholipase D in MCF-7 breast cancer cells. FEBS Lett. 2006 Oct 16; 580(24):5647-52.
    View in: PubMed
    Score: 0.272
  12. Zheng Y, Rodrik V, Toschi A, Shi M, Hui L, Shen Y, Foster DA. Phospholipase D couples survival and migration signals in stress response of human cancer cells. J Biol Chem. 2006 Jun 09; 281(23):15862-8.
    View in: PubMed
    Score: 0.264
  13. Rodrik V, Zheng Y, Harrow F, Chen Y, Foster DA. Survival signals generated by estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on Myc. Mol Cell Biol. 2005 Sep; 25(17):7917-25.
    View in: PubMed
    Score: 0.253
  14. Hui L, Rodrik V, Pielak RM, Knirr S, Zheng Y, Foster DA. mTOR-dependent suppression of protein phosphatase 2A is critical for phospholipase D survival signals in human breast cancer cells. J Biol Chem. 2005 Oct 28; 280(43):35829-35.
    View in: PubMed
    Score: 0.253
  15. Chen Y, Rodrik V, Foster DA. Alternative phospholipase D/mTOR survival signal in human breast cancer cells. Oncogene. 2005 Jan 20; 24(4):672-9.
    View in: PubMed
    Score: 0.243
  16. Hui L, Abbas T, Pielak RM, Joseph T, Bargonetti J, Foster DA. Phospholipase D elevates the level of MDM2 and suppresses DNA damage-induced increases in p53. Mol Cell Biol. 2004 Jul; 24(13):5677-86.
    View in: PubMed
    Score: 0.234
  17. Foster DA, Xu L. Phospholipase D in cell proliferation and cancer. Mol Cancer Res. 2003 Sep; 1(11):789-800.
    View in: PubMed
    Score: 0.220
  18. Chen Y, Zheng Y, Foster DA. Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene. 2003 Jun 19; 22(25):3937-42.
    View in: PubMed
    Score: 0.217
  19. Zhong M, Shen Y, Zheng Y, Joseph T, Jackson D, Foster DA. Phospholipase D prevents apoptosis in v-Src-transformed rat fibroblasts and MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun. 2003 Mar 14; 302(3):615-9.
    View in: PubMed
    Score: 0.213
  20. Xu L, Frankel P, Jackson D, Rotunda T, Boshans RL, D'Souza-Schorey C, Foster DA. Elevated phospholipase D activity in H-Ras- but not K-Ras-transformed cells by the synergistic action of RalA and ARF6. Mol Cell Biol. 2003 Jan; 23(2):645-54.
    View in: PubMed
    Score: 0.211
  21. Zhong M, Joseph T, Jackson D, Beychenok S, Foster DA. Elevated phospholipase D activity induces apoptosis in normal rat fibroblasts. Biochem Biophys Res Commun. 2002 Nov 08; 298(4):474-7.
    View in: PubMed
    Score: 0.208
  22. Joseph T, Bryant A, Frankel P, Wooden R, Kerkhoff E, Rapp UR, Foster DA. Phospholipase D overcomes cell cycle arrest induced by high-intensity Raf signaling. Oncogene. 2002 May 16; 21(22):3651-8.
    View in: PubMed
    Score: 0.202
  23. Shen Y, Zheng Y, Foster DA. Phospholipase D2 stimulates cell protrusion in v-Src-transformed cells. Biochem Biophys Res Commun. 2002 Apr 26; 293(1):201-6.
    View in: PubMed
    Score: 0.201
  24. Frias MA, Mukhopadhyay S, Lehman E, Walasek A, Utter M, Menon D, Foster DA. Phosphatidic acid drives mTORC1 lysosomal translocation in the absence of amino acids. J Biol Chem. 2020 01 03; 295(1):263-274.
    View in: PubMed
    Score: 0.170
  25. Foster DA. Phosphatidic acid and lipid-sensing by mTOR. Trends Endocrinol Metab. 2013 Jun; 24(6):272-8.
    View in: PubMed
    Score: 0.107
  26. Foster DA, Toschi A. Targeting mTOR with rapamycin: one dose does not fit all. Cell Cycle. 2009 Apr 01; 8(7):1026-9.
    View in: PubMed
    Score: 0.081
  27. Foster DA. Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells. Biochim Biophys Acta. 2009 Sep; 1791(9):949-55.
    View in: PubMed
    Score: 0.081
  28. Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol Cell Biol. 2009 Mar; 29(6):1411-20.
    View in: PubMed
    Score: 0.080
  29. Garcia A, Zheng Y, Zhao C, Toschi A, Fan J, Shraibman N, Brown HA, Bar-Sagi D, Foster DA, Arbiser JL. Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells. Clin Cancer Res. 2008 Jul 01; 14(13):4267-74.
    View in: PubMed
    Score: 0.077
  30. Mor A, Campi G, Du G, Zheng Y, Foster DA, Dustin ML, Philips MR. The lymphocyte function-associated antigen-1 receptor costimulates plasma membrane Ras via phospholipase D2. Nat Cell Biol. 2007 Jun; 9(6):713-9.
    View in: PubMed
    Score: 0.071
  31. Foster DA. Regulation of mTOR by phosphatidic acid? Cancer Res. 2007 Jan 01; 67(1):1-4.
    View in: PubMed
    Score: 0.069
  32. Cai D, Zhong M, Wang R, Netzer WJ, Shields D, Zheng H, Sisodia SS, Foster DA, Gorelick FS, Xu H, Greengard P. Phospholipase D1 corrects impaired betaAPP trafficking and neurite outgrowth in familial Alzheimer's disease-linked presenilin-1 mutant neurons. Proc Natl Acad Sci U S A. 2006 Feb 07; 103(6):1936-40.
    View in: PubMed
    Score: 0.065
  33. Cai D, Netzer WJ, Zhong M, Lin Y, Du G, Frohman M, Foster DA, Sisodia SS, Xu H, Gorelick FS, Greengard P. Presenilin-1 uses phospholipase D1 as a negative regulator of beta-amyloid formation. Proc Natl Acad Sci U S A. 2006 Feb 07; 103(6):1941-6.
    View in: PubMed
    Score: 0.065
  34. Foster DA. Targeting mTOR-mediated survival signals in anticancer therapeutic strategies. Expert Rev Anticancer Ther. 2004 Aug; 4(4):691-701.
    View in: PubMed
    Score: 0.059
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support